Lutathera: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2019 Aug 1

PMID 31362406

Citations 141

Authors

Ute Hennrich

Klaus Kopka

Affiliations

Soon will be listed here.

Abstract

As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera combines the radionuclide Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors. As a result, DNA single- and double-strand breaks are provoked, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions.

Citing Articles

Dynamic Visualization of Computer-Aided Peptide Design for Cancer Therapeutics.

Hou D, Zhou H, Tang Y, Liu Z, Su L, Guo J Drug Des Devel Ther. 2025; 19:1043-1065.

PMID: 39974609 PMC: 11837852. DOI: 10.2147/DDDT.S497126.

Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumab.

Rudd S, Van Zuylekom J, Cullinane C, Blyth B, Donnelly P Chem Sci. 2025; 16(9):3998-4005.

PMID: 39898305 PMC: 11783091. DOI: 10.1039/d4sc06969b.

Metastatic Insulinoma Managed With Continuous Glucose Monitoring in a Young Female Patient.

Bondarenko D, Thelmo F, Shirodkar M JCEM Case Rep. 2025; 3(2):luaf005.

PMID: 39866917 PMC: 11758144. DOI: 10.1210/jcemcr/luaf005.

FDA-approved drugs featuring macrocycles or medium-sized rings.

Du Y, Semghouli A, Wang Q, Mei H, Kiss L, Baecker D Arch Pharm (Weinheim). 2025; 358(1):e2400890.

PMID: 39865335 PMC: 11771699. DOI: 10.1002/ardp.202400890.

Exploring the Chemical Features and Biomedical Relevance of Cell-Penetrating Peptides.

Moreno-Vargas L, Prada-Gracia D Int J Mol Sci. 2025; 26(1.

PMID: 39795918 PMC: 11720145. DOI: 10.3390/ijms26010059.

References

Haberkorn U, Giesel F, Morgenstern A, Kratochwil C . The Future of Radioligand Therapy: α, β, or Both?. J Nucl Med. 2017; 58(7):1017-1018. DOI: 10.2967/jnumed.117.190124. View

Abuqbeitah M, Demir M, Uslu-Besli L, Yeyin N, Sonmezoglu K . Blood clearance and occupational exposure for Lu-DOTATATE compared to Lu-PSMA radionuclide therapy. Radiat Environ Biophys. 2017; 57(1):55-61. DOI: 10.1007/s00411-017-0721-6. View

Reubi J, Schar J, Waser B, Wenger S, Heppeler A, Schmitt J . Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3):273-82. DOI: 10.1007/s002590050034. View

Aslani A, Snowdon G, Bailey D, Schembri G, Bailey E, Pavlakis N . Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System. Asia Ocean J Nucl Med Biol. 2016; 3(2):107-15. PMC: 4937639. View

Turner J . An introduction to the clinical practice of theranostics in oncology. Br J Radiol. 2018; 91(1091):20180440. PMC: 6475944. DOI: 10.1259/bjr.20180440. View

Krenning E, Bakker W, Breeman W, Koper J, Kooij P, Ausema L . Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989; 1(8632):242-4. DOI: 10.1016/s0140-6736(89)91258-0. View

Xu C, Zhang H . Somatostatin receptor based imaging and radionuclide therapy. Biomed Res Int. 2015; 2015:917968. PMC: 4387942. DOI: 10.1155/2015/917968. View

Levine R, Krenning E . Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine. J Nucl Med. 2017; 58(Suppl 2):3S-9S. DOI: 10.2967/jnumed.116.186502. View

Milenic D, Brady E, Brechbiel M . Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004; 3(6):488-99. DOI: 10.1038/nrd1413. View

10.

Dash A, Chakraborty S, Pillai M, Knapp Jr F . Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm. 2015; 30(2):47-71. DOI: 10.1089/cbr.2014.1741. View

11.

Elschot M, Vermolen B, Lam M, de Keizer B, van den Bosch M, W A M de Jong H . Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS One. 2013; 8(2):e55742. PMC: 3566032. DOI: 10.1371/journal.pone.0055742. View

12.

Coenen H, Gee A, Adam M, Antoni G, Cutler C, Fujibayashi Y . Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight. Nucl Med Biol. 2017; 55:v-xi. DOI: 10.1016/j.nucmedbio.2017.09.004. View

13.

BRAZEAU P, Vale W, Burgus R, Ling N, Butcher M, Rivier J . Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973; 179(4068):77-9. DOI: 10.1126/science.179.4068.77. View

14.

de Jong M, Rolleman E, Bernard B, Visser T, Bakker W, Breeman W . Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med. 1996; 37(8):1388-92. View

15.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B . Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2):125-135. PMC: 5895095. DOI: 10.1056/NEJMoa1607427. View

16.

Brechbiel M . Targeted alpha-therapy: past, present, future?. Dalton Trans. 2007; (43):4918-28. PMC: 2408446. DOI: 10.1039/b704726f. View

17.

Kwekkeboom D, Kam B, Van Essen M, Teunissen J, van Eijck C, Valkema R . Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2009; 17(1):R53-73. DOI: 10.1677/ERC-09-0078. View

18.

Kim Y, Kim Y, Um S, Seo Y, Park E, Oh S . Usefulness of Bremsstrahlung Images after Intra-arterial Y-90 Resin Microphere Radioembolization for Hepatic Tumors. Nucl Med Mol Imaging. 2014; 45(1):59-67. PMC: 4042949. DOI: 10.1007/s13139-010-0066-4. View

19.

Coenen H, Gee A, Adam M, Antoni G, Cutler C, Fujibayashi Y . Open letter to journal editors on: International consensus radiochemistry nomenclature guidelines. J Labelled Comp Radiopharm. 2018; 61(4):402-404. DOI: 10.1002/jlcr.3604. View